Related Experiment Videos
Platelet serotonin concentrations in medicated schizophrenic patients
Y Kaneda1, A Fujii, I Nagamine
1Department of Neuropsychiatry, The University of Tokushima School of Medicine, Japan. kaneday@clin.med.tokushima-u.ac.jp
Summary
Neuroleptic medications significantly lower platelet serotonin (5-HT) levels in schizophrenia patients. These reduced serotonin levels do not correlate with psychopathology or extrapyramidal symptoms in treated individuals.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder.
- Neuroleptic medications are primary treatments for schizophrenia.
- Platelet serotonin (5-HT) levels are studied as a potential biomarker.
Purpose of the Study:
- To investigate the impact of neuroleptic administration on platelet serotonin (5-HT) levels in schizophrenia.
- To examine the relationship between platelet 5-HT levels, psychopathology, and extrapyramidal symptoms (EPS) in medicated schizophrenia patients.
Main Methods:
- Study included 49 regularly medicated schizophrenia inpatients diagnosed via DSM-IV criteria.
- Patients were divided into lower (LL) and higher (HL) platelet 5-HT level groups.
- Psychotic symptoms and EPS were assessed using standardized rating scales.
Main Results:
- Mean platelet 5-HT levels were significantly lower in medicated schizophrenia patients compared to normal subjects.
- Mean blood monoamine oxidase (MAO) levels tended to be lower in schizophrenia patients.
- No significant differences in positive symptoms, negative symptoms, or EPS were found between LL and HL groups.
- Platelet 5-HT levels did not correlate with blood MAO concentrations.
Conclusions:
- Neuroleptic treatment appears to reduce platelet 5-HT levels in schizophrenia.
- Platelet 5-HT levels in neuroleptic-treated schizophrenia patients do not serve as indicators of psychopathology or EPS severity.